. 2025 Apr 20;85(6):777–799. doi: 10.1007/s40265-025-02176-y

Table 4.

Results of phase III efficacy endpoints of centhaquine studies

Efficacy endpoints	Time	Percent (number) of patients	p-value
SBP > 90 mmHg	12 h	Centhaquine: 96.9 (63)	0.07
SBP > 90 mmHg	12 h	Control: 87.5 (28)	0.07
SBP ≥ 110 mmHg	24 h	Centhaquine: 79.7 (51)	0.04
SBP ≥ 110 mmHg	24 h	Control: 60.6 (20)	0.04
SBP ≥ 120 mmHg	48 h	Centhaquine: 56.2 (36)	0.39
SBP ≥ 120 mmHg	48 h	Control: 46.9 (15)	0.39
DBP > 65 mmHg	12 h	Centhaquine: 72.3 (47)	0.24
DBP > 65 mmHg	12 h	Control: 60.6 (20)	0.24
DBP ≥ 70 mmHg	24 h	Centhaquine: 76.6 (49)	0.01
DBP ≥ 70 mmHg	24 h	Control: 51.5 (17)	0.01
DBP ≥ 80 mmHg	48 h	Centhaquine: 50.0 (32)	0.08
DBP ≥ 80 mmHg	48 h	Control: 31.2 (10)	0.08
Blood lactate ≤ 1.5 mmol/L	3 d	Centhaquine: 69.3 (43)	0.03
Blood lactate ≤ 1.5 mmol/L	3 d	Control: 46.9 (15)	0.03
Base deficit < − 2.0 mmol/L	3 d	Centhaquine: 69.8 (44)	0.01
Base deficit < − 2.0 mmol/L	3 d	Control: 43.7 (14)	0.01
Mortality	28 d	Centhaquine: 2.9 (2)	0.07
Mortality	28 d	Control: 11.8 (4)	0.07

d days, DBP diastolic blood pressure, h hours, SBP systolic blood pressure